German pricing rules hit Eisai’s Halaven
Drug has “no additional benefit” in metastatic liposarcoma, says IQWiG.
X
German pricing rules hit Eisai’s Halaven
https://pharmaphorum.com/news/german-pricing-rules-hit-eisais-halaven/
Iqwig
The biggest pharma stories of 2016 so far
The top 10 pharma milestones of the year to date.
German watchdog criticises EMA adaptive pathways approval
Cost effectiveness agency critical of real world evidence plans